

# ANTI-CANCER COMPOUNDS FOR TREATMENT OF CANCER AND AUTOIMMUNE INFLAMMATION (RFT-531)

#### **Invention Summary:**

**Cyclo-oxygenase-2 (COX-2)** over-expression is a known marker for cancer cell initiation, growth and consequent metastasis. COX-2 catalyzes the oxidation of omega 6 fatty acid - arachidonic acid, producing metabolites such as prostaglandins that are known to instigate various cancers. Scientists at North Dakota State University have developed an anti-cancer compound that indirectly targets the over-expression of COX-2, with potential to treat multiple cancer types. Specifically, this compound targets delat-5-saturase (D5D) and provides anti-cancer benefits in two ways: 1. Down regulation of 'pro-cancer' prostaglandins and 2. elevated production of anti-cancer compound, **dihomo-γ-linolenic acid (DGLA)** and its metabolite, **8- hydroxy octanoic acid (8-HOA)**. A common strategy has been to completely block COX-2, shutting down its beneficial aspects in order to eliminate the negative aspects. NDSU's technology selectively turns down COX-2's negative aspects, while taking advantage of COX-2 over expression to boost production of 8- HOA. To our knowledge, this technology represents the first anti-cancer compound to take advantage of COX-2 over-expression in tumors and has been successfully tested in the lab using mice bearing solid tumors for breast, colon, pancreatic, and lung cancers.




Figure: Reduced tumor growth in pancreatic xenograft tumors up to 60%




Figure: Reduced tumor growth in colon xenograft tumors up to 67%

NDSU

# RESEARCH FOUNDATION

### **Benefits:**

- 1. Targeted strategy with tested application in cancer management and prevention.
- 2. Probable treatment in both benign and metastatic (solid or invasive) tumors.
- Effective in multiple solid tumor types reduced growth rate of tumors by 50% to 70% in mice bearing breast, colon, pancreatic, and lung tumors
- Preliminary data on combination therapy with conventional chemotherapeutics reflects additional restriction of tumor growth and metastasis.
- Additionally, this targeted strategy can be used for treatment of autoimmune and inflammatory conditions.




Figure: Anti-tumor outcomes from 8mg/ mice treatments in xenograft tumors

### Patents:

This technology is the subject of <u>Issued US patent no. 10,639,313</u> and is available for licensing/partnering opportunities.

### **Phase of Development:**

This technology has successfully completed laboratory testing with reproducible results.

## Contact:

Saurabhi Satam Business Development and Licensing Associate <u>ssatam@ndsurf.org</u> <u>http://www.ndsuresearchfoundation.org/</u> 701-231-8173